Saitama, Japan

Tomoyuki Sada

This inventor holds 1 USPTO granted patent. Top assignee: Toa Eiyo Ltd.. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tomoyuki Sada. Retrieved from https://idiyas.com/inventor/tomoyuki-sada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tomoyuki Sada: Innovator in Arylamidrazone Derivatives

Introduction

Tomoyuki Sada is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his work on arylamidrazone derivatives. His innovative approach has led to the development of compounds with potential therapeutic applications.

Latest Patents

Tomoyuki Sada holds 1 patent related to arylamidrazone derivatives. This patent describes compounds that exhibit antagonistic action against S1P receptors, which are crucial in various biological processes. The invention includes a formula for these derivatives or their pharmaceutically acceptable salts, highlighting their potential in medical applications.

Career Highlights

Sada is currently employed at Toa Eiyo Ltd., a company known for its commitment to advancing pharmaceutical research and development. His work at the company has allowed him to focus on innovative solutions that address unmet medical needs.

Collaborations

Throughout his career, Tomoyuki Sada has collaborated with esteemed colleagues, including Shin-ya Ohnuma and Takeshi Hasegawa. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Tomoyuki Sada's contributions to the field of pharmaceuticals through his innovative work on arylamidrazone derivatives demonstrate his commitment to advancing medical science. His patent and collaborations reflect a dedication to improving therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…